BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17445839)

  • 1. Loss of nuclear BRCA1 protein staining in normal tissue cells derived from BRCA1 and BRCA2 mutation carriers.
    De Brakeleer S; Bogdani M; De Grève J; Decock J; Sermijn E; Bonduelle M; Goelen G; Teugels E
    Mutat Res; 2007 Jun; 619(1-2):104-12. PubMed ID: 17445839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphocytes of BRCA1 and BRCA2 germ-line mutation carriers, with or without breast cancer, are not abnormally sensitive to the chromosome damaging effect of moderate folate deficiency.
    Beetstra S; Salisbury C; Turner J; Altree M; McKinnon R; Suthers G; Fenech M
    Carcinogenesis; 2006 Mar; 27(3):517-24. PubMed ID: 16162645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
    Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
    Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic alterations in histopathologically normal breast tissue from BRCA1 mutation carriers may be caused by BRCA1 haploinsufficiency.
    Rennstam K; Ringberg A; Cunliffe HE; Olsson H; Landberg G; Hedenfalk I
    Genes Chromosomes Cancer; 2010 Jan; 49(1):78-90. PubMed ID: 19839046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice versa.
    Staff S; Isola JJ; Johannsson O; Borg A; Tanner MM
    Br J Cancer; 2001 Oct; 85(8):1201-5. PubMed ID: 11710835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer.
    Pierce LJ; Levin AM; Rebbeck TR; Ben-David MA; Friedman E; Solin LJ; Harris EE; Gaffney DK; Haffty BG; Dawson LA; Narod SA; Olivotto IA; Eisen A; Whelan TJ; Olopade OI; Isaacs C; Merajver SD; Wong JS; Garber JE; Weber BL
    J Clin Oncol; 2006 Jun; 24(16):2437-43. PubMed ID: 16636335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.
    Aaltonen K; Blomqvist C; Amini RM; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H
    Clin Cancer Res; 2008 Apr; 14(7):1976-83. PubMed ID: 18381935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers.
    Antoniou AC; Shenton A; Maher ER; Watson E; Woodward E; Lalloo F; Easton DF; Evans DG
    Breast Cancer Res; 2006; 8(6):R72. PubMed ID: 17187672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer.
    Cavalli LR; Singh B; Isaacs C; Dickson RB; Haddad BR
    Cancer Genet Cytogenet; 2004 Feb; 149(1):38-43. PubMed ID: 15104281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allele imbalance, or loss of heterozygosity, in normal breast epithelium of sporadic breast cancer cases and BRCA1 gene mutation carriers is increased compared with reduction mammoplasty tissues.
    Larson PS; Schlechter BL; de las Morenas A; Garber JE; Cupples LA; Rosenberg CL
    J Clin Oncol; 2005 Dec; 23(34):8613-9. PubMed ID: 16314623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No association between BRCA mutations and sex ratio in offspring of Pakistani BRCA mutation carriers.
    Rashid MU; Torres D; Zaidi A; Rasheed F; Sultan F; Shakoori AR; Amin A; Hamann U
    Breast Cancer Res Treat; 2008 Jan; 107(1):155-6. PubMed ID: 18043900
    [No Abstract]   [Full Text] [Related]  

  • 13. Deletions on chromosome 4 in sporadic and BRCA mutated tumors and association with pathological variables.
    Johannsdottir HK; Johannesdottir G; Agnarsson BA; Eerola H; Arason A; Johannsson OT; Heikkilä P; Egilsson V; Olsson H; Borg A; Nevanlinna H; Barkardottir RB
    Anticancer Res; 2004; 24(5A):2681-7. PubMed ID: 15521105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer.
    Melchor L; Honrado E; Huang J; Alvarez S; Naylor TL; García MJ; Osorio A; Blesa D; Stratton MR; Weber BL; Cigudosa JC; Rahman N; Nathanson KL; Benítez J
    Clin Cancer Res; 2007 Dec; 13(24):7305-13. PubMed ID: 18094411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of nuclear BRCA1 localization in breast carcinoma is age dependent.
    Bogdani M; Teugels E; De Grève J; Bourgain C; Neyns B; Pipeleers-Marichal M
    Virchows Arch; 2002 Mar; 440(3):274-9. PubMed ID: 11889597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
    Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.
    Birgisdottir V; Stefansson OA; Bodvarsdottir SK; Hilmarsdottir H; Jonasson JG; Eyfjord JE
    Breast Cancer Res; 2006; 8(4):R38. PubMed ID: 16846527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methionine-dependence phenotype in the de novo pathway in BRCA1 and BRCA2 mutation carriers with and without breast cancer.
    Beetstra S; Suthers G; Dhillon V; Salisbury C; Turner J; Altree M; McKinnon R; Fenech M
    Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2565-71. PubMed ID: 18842997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical management of BRCA1 and BRCA2 mutation carriers.
    Domchek SM; Armstrong K; Weber BL
    Nat Clin Pract Oncol; 2006 Jan; 3(1):2-3. PubMed ID: 16407858
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study.
    Lee E; Ma H; McKean-Cowdin R; Van Den Berg D; Bernstein L; Henderson BE; Ursin G
    Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3170-8. PubMed ID: 18990759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.